SCHEMBL24619337

SCHEMBL24619337

NCCCNCC(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.52
CA6 P23280 5/20 0.52
CA7 P43166 5/20 0.52
CA9 Q16790 5/20 0.52
CA14 Q9ULX7 5/20 0.52
CA5B Q9Y2D0 5/20 0.52
CA2 P00918 4/20 0.52
CA4 P22748 4/20 0.52
CA5A P35218 4/20 0.52
ALOX15 P16050 3/20 0.52
CASP2 P42575 2/20 0.52
F13A1 P00488 2/20 0.52
CYP1A2 P05177 2/20 0.52
THPO P40225 2/20 0.52
MEN1 O00255 2/20 0.52
RECQL P46063 2/20 0.52
KMT2A Q03164 2/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CA3 P07451 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324465 0.89
SCHEMBL6811425 0.81 PKM (0.31) CA12CA6CA7CA9CA14
SCHEMBL6563347 0.80 CA12 (0.48) CA12CA6CA7CA9CA14
SCHEMBL14064945 0.78 CA5A (0.44) CA12CA6CA7CA9CA14
SCHEMBL9826780 0.77 CA12 (0.56) CA12CA6CA7CA9CA14
SCHEMBL9834907 0.77 CA12 (0.44) CA12CA6CA7CA9CA14
SCHEMBL9826394 0.77 CA12 (0.50) CA12CA6CA7CA9CA14
SCHEMBL10045231 0.76 CA5A (0.43) CA12CA6CA7CA9CA14
SCHEMBL16681134 0.74 ALDH1A1 (0.30) PKMTSHRTDP1ALDH1A1
SCHEMBL2608049 0.74 TSHR (0.50) CA12CA7CA14CA2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182308-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-05-24 EP disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed
WO-2022013307-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 CA12 4693/4885CA6 4643/4885CA7 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.